Marengo Therapeutics
1 known investors
Marengo Therapeutics develops immunotherapies focused on activating specific immune cells to treat cancer. The company works in the oncology and immuno-oncology biotech space.
BiotechHealthtech
Investors Β· 1
Competitors Β· 2
by search overlapBioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode Therapeutics13 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Companies competing with Marengo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Marengo Therapeutics do?
- Marengo Therapeutics develops immunotherapies focused on activating specific immune cells to treat cancer. The company works in the oncology and immuno-oncology biotech space.
- Who are Marengo Therapeutics's investors?
- Marengo Therapeutics's investors include Scion Life Sciences.